BioXcel Therapeutics (BTAI) Income towards Parent Company (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Income towards Parent Company of -$14.2 million for Q1 2026, down 2.87% year-over-year from -$14.6 million in Q1 2025, and down 101.19% quarter-over-quarter from -$7.1 million in Q4 2025.
BioXcel Therapeutics (BTAI) Income towards Parent Company (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$14.2 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 2.87% year-over-year to -$14.2 million; the TTM figure through Mar 2026 stood at -$59.0 million (up 1.35% YoY), while the FY2025 annual figure was -$66.4 million, up 74.15% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$14.2 million, down from -$7.1 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$7.1 million in Q4 2025, with the low at -$169.8 million in Q4 2022.
- The 5-year median for Income towards Parent Company is -$21.0 million (2023), against an average of -$43.1 million.
- The sharpest annual moves came in 2022 and 2023: Income towards Parent Company tumbled 549.88% in 2022, then jumped 87.64% in 2023.
- BioXcel Therapeutics' Income towards Parent Company stood at -$169.8 million in 2022, then surged by 87.64% to -$21.0 million in 2023, then surged by 65.5% to -$7.2 million in 2024, then increased by 2.46% to -$7.1 million in 2025, then slumped by 101.19% to -$14.2 million in 2026.
- Business Quant data shows BTAI's Income towards Parent Company at -$14.2 million in Q1 2026, -$7.1 million in Q4 2025, and -$17.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | BioXcel Therapeutics | 24.40 Mn | 24.40 Mn | 160,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.32 Mn |
| Mar 31, 2026 | -14.21 Mn |
| Dec 31, 2025 | -7.06 Mn |
| Sep 30, 2025 | -17.92 Mn |
| Jun 30, 2025 | -19.84 Mn |
| Mar 31, 2025 | -13.81 Mn |
| Dec 31, 2024 | -7.24 Mn |
| Sep 30, 2024 | -18.47 Mn |
| Jun 30, 2024 | -20.33 Mn |
| Mar 31, 2024 | -26.82 Mn |
| Dec 31, 2023 | -20.99 Mn |
| Sep 30, 2023 | -54.55 Mn |
| Jun 30, 2023 | -60.01 Mn |
| Mar 31, 2023 | -85.25 Mn |
| Dec 31, 2022 | -169.78 Mn |
| Sep 30, 2022 | -58.53 Mn |
| Jun 30, 2022 | -59.76 Mn |
| Mar 31, 2022 | -78.15 Mn |
| Dec 31, 2021 | -26.13 Mn |
| Sep 30, 2021 | -93.38 Mn |